Cargando…

Plasminogen activator inhibitor type 2 in breast cancer.

The serine protease urokinase plasminogen activator (uPA) is causally involved in cancer invasion and metastasis. Activity of this protease in vivo is controlled principally by two inhibitors, one of which is plasminogen activator inhibitor type 2 (PAI-2). In this study, we show that PAI-2 levels we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Duggan, C., Kennedy, S., Kramer, M. D., Barnes, C., Elvin, P., McDermott, E., O'Higgins, N., Duffy, M. J.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1997
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228003/ https://www.ncbi.nlm.nih.gov/pubmed/9303361

Ejemplares similares

Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry.
por: Kennedy, S., et al.
Publicado: (1998)

Assay of matrix metalloproteases types 8 and 9 by ELISA in human breast cancer.
por: Duffy, M. J., et al.
Publicado: (1995)

Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer.
por: Remacle, A. G., et al.
Publicado: (1998)

Metalloproteinases: role in breast carcinogenesis, invasion and metastasis
por: Duffy, Michael J, et al.
Publicado: (2000)

Overexpression of the Ets-1 transcription factor in human breast cancer
por: Buggy, Y, et al.
Publicado: (2004)

Expression of survivin and its splice variants survivin-2B and survivin-ΔEx3 in breast cancer
por: Ryan, B, et al.
Publicado: (2005)

Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.
por: Knoop, A., et al.
Publicado: (1998)

Prognostic importance of survivin in breast cancer
por: Kennedy, S M, et al.
Publicado: (2003)

Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.
por: Bouchet, C., et al.
Publicado: (1994)

A positive role for PEA3 in HER2-mediated breast tumour progression
por: Myers, E, et al.
Publicado: (2006)

Localization of Urokinase‐type Plasminogen Activator, Plasminogen Activator Inhibitor‐1, 2 and Plasminogen in Colon Cancer
por: Naitoh, Hiroyuki, et al.
Publicado: (1995)

Elevated expression and altered processing of fibulin-1 protein in human breast cancer
por: Greene, L M, et al.
Publicado: (2003)

Thrombin and plasmin generation in patients with plasminogen or plasminogen activator inhibitor type 1 deficiency
por: Saes, Joline L., et al.
Publicado: (2019)

Structural basis of specific inhibition of tissue-type plasminogen activator by plasminogen activators inhibitor-1
por: Gong, Lihu, et al.
Publicado: (2016)

Role of tissue-type plasminogen activator and plasminogen activator inhibitor-1 in psychological stress and depression
por: Tsai, Shih-Jen
Publicado: (2017)

Plasminogen Activator Inhibitor-1 Protects Mice Against Cardiac Fibrosis by Inhibiting Urokinase-type Plasminogen Activator-mediated Plasminogen Activation
por: Gupta, Kamlesh K., et al.
Publicado: (2017)

Chemical Antagonists of Plasminogen Activator Inhibitor-1: Mechanisms of Action and Therapeutic Potential in Vascular Disease
por: Simone, Tessa M, et al.
Publicado: (2014)

Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors
por: Jahkola, T, et al.
Publicado: (1999)

Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors
Publicado: (1987)

The role of major duct excision and microdochectomy in the detection of breast carcinoma
por: Dillon, Mary F, et al.
Publicado: (2006)

Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors
por: Lampelj, Maja, et al.
Publicado: (2015)

Uncharged isocoumarin-based inhibitors of urokinase-type plasminogen activator
por: Heynekamp, Justin J, et al.
Publicado: (2006)

Inverse relationship between ER-β and SRC-1 predicts outcome in endocrine-resistant breast cancer
por: Myers, E, et al.
Publicado: (2004)

The effects of residual platelets in plasma on plasminogen activator inhibitor-1 and plasminogen activator inhibitor-1-related assays
por: Pieters, Marlien, et al.
Publicado: (2017)

Glucocorticoid-modulated gene expression of tissue- and urinary-type plasminogen activator and plasminogen activator inhibitor 1 and 2
Publicado: (1988)

Independent prognostic value of angiogenesis and the level of plasminogen activator inhibitor type 1 in breast cancer patients
por: Hansen, S, et al.
Publicado: (2003)

Effect of Plasminogen Activator Inhibitor-1 and Tissue Plasminogen Activator Polymorphisms on Susceptibility to Type 2 Diabetes in Malaysian Subjects
por: Al-Hamodi, Zaid, et al.
Publicado: (2012)

Tissue plasminogen activator and plasminogen activator inhibitor type 1 gene polymorphism in patients with gastric ulcer complicated with bleeding.
por: Kim, Hong-Soo, et al.
Publicado: (2003)

Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects
por: Al-Hamodi, Zaid, et al.
Publicado: (2011)

Premature delivery impacts the concentration of plasminogen activators and a plasminogen activator inhibitor and the plasmin activity in human milk
por: Demers-Mathieu, Veronique, et al.
Publicado: (2022)

Role of urokinase plasminogen activator and plasminogen activator inhibitor mRNA expression as prognostic factors in molecular subtypes of breast cancer
por: Witzel, Isabell, et al.
Publicado: (2014)

Causal Effect of Plasminogen Activator Inhibitor Type 1 on Coronary Heart Disease
por: Song, Ci, et al.
Publicado: (2017)

Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer
por: Witte, J H de, et al.
Publicado: (1999)

External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts.
por: Sweep, C. G., et al.
Publicado: (1998)

Relationship between tissue plasminogen activator, plasminogen activator inhibitor and CT image in chronic subdural hematoma.
por: Lim, D. J., et al.
Publicado: (1995)

Obesity and Breast Cancer: The Roles of Peroxisome Proliferator-Activated Receptor-γ and Plasminogen Activator Inhibitor-1
por: Carter, Jennifer C., et al.
Publicado: (2009)

Plasminogen activator inhibitor type 1 regulates microglial motility and phagocytic activity
por: Jeon, Hyejin, et al.
Publicado: (2012)

Is the Urokinase Plasminogen Activator/Plasminogen Activator Inhibitor-1 Ratio a Marker of Sonographic Septations in Pleural Infection?
por: Yasuma, Taro, et al.
Publicado: (2022)

The role of plasminogen activator inhibitor-2 in pneumococcal meningitis
por: Teske, Nina C., et al.
Publicado: (2022)

Tissue Plasminogen Activator and Plasminogen Activator Inhibitor-1 Levels in Patients with Acute Paraquat Intoxication
por: Seok, Su-Jin, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_3sr3t313u46spl0a894e7paka8